Modular Membrane Fusion Proteins for Intracellular Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Natural membrane fusion proteins, such as viral envelope glycoproteins or SNARE proteins, are difficult to engineer and can be immunogenic or toxic, limiting their application in intracellular drug delivery.
Innovation Solution
Designing nucleic acids encoding polypeptides with specific amino acid sequences that form membrane fusion proteins, comprising a formula of X1-X2-X3, where X1 is highly identical to selected sequences, X2 is a juxtamembrane domain, and X3 is a transmembrane domain, to create modular and easier-to-engineer fusion proteins for inducing membrane fusion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural membrane fusion proteins (viral envelope glycoproteins or SNARE proteins) are used, then membrane fusion function is achieved, but they are hard to engineer and may be immunogenic or toxic
Solution Approach 1:
The membrane fusion protein is divided into three distinct functional domains: X1 (amino acid sequence domain), X2 (juxtamembrane domain), and X3 (transmembrane domain). This segmentation allows each domain to be independently designed and optimized, making the overall protein easier to engineer while maintaining membrane fusion function.
Solution Approach 2:
The patent specifies precise parameter requirements for each domain: X1 must be at least 50-100% identical to selected sequences, X2 must be at least 50-100% identical to specific JMD sequences, and X3 must be at least 50-100% identical to specific TMD sequences. These parameter changes enable systematic engineering of the protein while preserving essential fusion functionality.
2Reliability
If natural membrane fusion proteins are used, then membrane fusion function is achieved, but they may be immunogenic or toxic for biological applications
Solution Approach 1:
The patent creates synthetic membrane fusion proteins that copy the essential functional features of natural proteins (viral envelope glycoproteins or SNARE proteins) through the X1-X2-X3 domain structure, while avoiding the harmful immunogenic and toxic characteristics of the natural originals. The designed protein achieves membrane fusion function without eliciting unwanted immune responses or toxicity.
3Ease of manufacture
If newly designed membrane fusion proteins are used, then ease of engineering is improved, but membrane fusion efficiency must be maintained
Solution Approach 1:
By segmenting the protein into X1, X2, and X3 domains with specific functional assignments, the patent achieves both ease of engineering (through modular design) and maintained fusion efficiency (through precise domain sequence requirements). Each segment can be independently optimized for engineering convenience while the combined structure ensures biological functionality.
Solution Approach 2:
The patent establishes specific parameter thresholds (50-100% sequence identity requirements for each domain) that ensure the designed protein maintains membrane fusion efficiency while being easier to engineer than natural proteins. These parameters balance synthetic design flexibility with biological functional requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The designed polypeptides efficiently induce membrane fusion, enhancing intracellular drug delivery by forming hetero-oligomeric complexes in lipid bilayer membranes, promoting fusion of cells or liposomes, and allowing for therapeutic or diagnostic cargo delivery.
Implementation Method 1
Membrane fusion is a process of merging of two membranes. In a biological system, membrane fusion proteins catalyze this process by pulling two lipid bilayer membranes into close proximity and forcing them to merge into a single membrane.
Data Source
AI summary
Nucleic acids and expression vectors, and host cells or vesicles containing them, are provided that encode polypeptides and fusion proteins capable of forming hetero-oligomeric complexes capable of inducing membrane or vesicle fusion, and their use as delivery vehicles.